FdaApplication
NDA 022145
Identifiers
- fda_app_no: NDA022145
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2007-10-12 |
Revenue by product
ISENTRESS HD
| Period | Revenue |
|---|---|
| Q2 2026 | $60.0M |
| Q1 2026 | $59.0M |
| Q4 2025 | $67.0M |
| Q3 2025 | $82.0M |
| Q2 2025 | $86.0M |
| Q1 2025 | $90.0M |
| Q4 2024 | $92.0M |
| Q3 2024 | $102.0M |
| Q2 2024 | $89.0M |
| Q1 2024 | $111.0M |
| Q4 2023 | $106.0M |
| Q3 2023 | $119.0M |
| Q2 2023 | $136.0M |
| Q1 2023 | $123.0M |
| Q4 2022 | $167.0M |
| Q3 2022 | $161.0M |
| Q2 2022 | $147.0M |
| Q1 2022 | $158.0M |
| Q4 2021 | $179.0M |
| Q3 2021 | $189.0M |
| Q2 2021 | $192.0M |
| Q1 2021 | $209.0M |
| Q4 2020 | $211.0M |
| Q3 2020 | $205.0M |
| Q2 2020 | $196.0M |
| Q1 2020 | $245.0M |
| Q4 2019 | $223.0M |
| Q3 2019 | $250.0M |
| Q2 2019 | $247.0M |
| Q1 2019 | $255.0M |
| Q4 2018 | $280.0M |
| Q3 2018 | $275.0M |
| Q2 2018 | $305.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ISENTRESS | RALTEGRAVIR POTASSIUM | EQ 400MG BASE | TABLET;ORAL |
| ISENTRESS HD | RALTEGRAVIR POTASSIUM | EQ 600MG BASE | TABLET;ORAL |
2 products